Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Marginal Zone Lymphoma
Related studies linked through entity extraction aliases.
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
- Status
- COMPLETED
- Phase
- PHASE1
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
- Status
- COMPLETED
- Phase
- PHASE1
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
- Status
- TERMINATED
- Phase
- PHASE2
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Status
- RECRUITING
- Phase
- N/A
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Obinutuzumab in Marginal Zone Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2